All In Biotech

Drug Trial Radar · NCT03382964

Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years

Last checked: Nov 19, 2026Latest source record: Aug 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Mar 5, 2018

Primary completion

Jul 13, 2018

Study completion Jul 28, 2019

Sponsor

Lead sponsor
Valneva Austria GmbHIndustry
Sponsor type
Industry
First posted
Dec 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Randomized, observer-blinded, multicenter, dose-escalation Phase 1 clinical study investigating three dose levels of VLA1553 after a single immunization. 120 study participants will be enrolled into the study to receive three different doses (30 subjects in the low and medium and 60 subjects in the high dose group). Vaccination will be given intramuscularly on Day 0. As safety precaution, the study will begin with enrolment of 20 sentinel subjects in an open-label fashion. Thereafter, subjects will be enrolled in a blinded, randomized manner in the three study arms. A re-vaccination will be given at Month 6 or Month 12 to confirm that a single vaccination will be sufficient to induce high titer neutralizing antibodies and protect subjects from CHIKV viremia. Study participants will be followed up until 13 months after initial vaccination.

Conditions

  • Chikungunya

Interventions

  • VLA1553Biological

    I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of solicited injection site reactionsTime frame: up to Day 14 after single vaccination
  2. Severity of solicited injection site reactionsTime frame: up to Day 14 after single vaccination
  3. Frequency of solicited systemic reactionsTime frame: up to Day 14 after single vaccination
  4. Severity of solicited systemic reactionsTime frame: up to Day 14 after single vaccination

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Optimal Research, LLC

    Huntsville, Alabama

  • Optimal Research, LLC

    Peoria, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.